Apomorphine Hydrochloride Injection (Britannia Pharmaceuticals)

盐酸阿扑吗啡注射液 (Britannia Pharmaceuticals)

Report date: 2025/03/12 20:00:47

Base Information

Drug NameApomorphine Hydrochloride Injection (Britannia Pharmaceuticals)
Drug Alias NameApomorphine Hydrochloride SubcutaneousApokinonApokynApomineBritaject +[11] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionDopamine receptors agonists
TargetsDopamine receptors
Therapy Area/IndicationsParkinson Disease
Global Approved IndicationsParkinson Disease
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date2000/01/01
Country/TerritoryNetherlandsDenmarkAustria +[8] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesBritannia Pharmaceuticals Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIgnis Therapeutics (Suzhou) LtdLaboratoire AguettantBritannia Pharmaceuticals Ltd +[4] 
Inactive CompaniesN/A
Active IndicationsParkinson Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A